1. Glioma nanotherapy: Unleashing the synergy of dual-loaded DIM and TMZ.
- Author
-
Sarkar S, Kumar S, Saha G, Basu M, and Ghosh MK
- Subjects
- Animals, Humans, Cell Line, Tumor, Apoptosis drug effects, Indoles administration & dosage, Indoles chemistry, Indoles pharmacology, Mice, Nanoparticles chemistry, ErbB Receptors metabolism, ErbB Receptors antagonists & inhibitors, DNA Damage drug effects, Glioma drug therapy, Glioma pathology, Polyglycolic Acid chemistry, Cell Survival drug effects, Lactic Acid chemistry, Dacarbazine analogs & derivatives, Dacarbazine administration & dosage, Dacarbazine chemistry, Dacarbazine pharmacology, Antineoplastic Agents, Alkylating administration & dosage, Antineoplastic Agents, Alkylating pharmacology, Antineoplastic Agents, Alkylating pharmacokinetics, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols pharmacology, Mice, Nude, Temozolomide administration & dosage, Temozolomide pharmacology, Polylactic Acid-Polyglycolic Acid Copolymer chemistry, Brain Neoplasms drug therapy, Brain Neoplasms pathology, Drug Synergism, Glioblastoma drug therapy, Glioblastoma pathology
- Abstract
Glioblastoma multiforme (GBM) is a highly aggressive form of primary brain tumor in adults, which unfortunately has an abysmal prognosis and poor survival rates. The reason behind the poor success rate of several FDA-approved drug is mainly attributed to insufficient drug distribution to the tumor site across the blood-brain barrier (BBB) and induction of resistance. In this study, we have developed a novel nanotherapeutic approach to achieve our goal. PLGA-based nanoencapsulation of both Temozolomide (TMZ) and EGFR inhibitor 3,3'-diindoyl methane (DIM) in a combinatorial approach enhances the delivery of them together. Their synergistic mode of actions, significantly enhances the cytotoxic effect of TMZ in vitro and in vivo. Moreover, the dual-loaded nanoformulation works more efficiently on DNA damage and apoptosis, resulting in a several-fold reduction in tumor burden in vivo, systemic drug toxicity, and increased survival. These findings suggest the preclinical potential of this new treatment strategy., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF